Market Newsdesk

Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models

Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance

Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly evolving TROP2 ADC class expected to reach ~$12B by 2033

¹

TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research (AACR) Annual Meeting 2026. Access the poster here.

Unlike current TROP2-targeting ADCs that use Topoisomerase I Inhibitor (Inh.) payloads, AKTX-101 has the potential to address resistance to Topoisomerase I Inh. ADCs and contribute to durable anti-tumor efficacy due to the payload’s unique cytotoxic and immune-activating mechanisms of action.

The preclinical data compares the performance of AKTX-101 versus TROP2 ADCs with Topoisomerase I Inh. payloads in the killing of different cancer types driven by different cancer genes (oncogenes). AKTX-101’s ability to kill cancer cells at lower concentrations vs. TROP2 ADCs using Topoisomerase I Inh. payloads suggests that AKTX-101 is a more potent drug.

The preclinical data was published recently as an abstract in Cancer Research, an AACR journal.

Here, AKTX-101 demonstrated greater potency and/or greater maximum cancer cell killing relative to TROP2 ADC Topoisomerase I Inh. payloads in cancers of the bladder, lung and breast. AKTX-101 demonstrated sub-nanomolar potency in all bladder cancer lines tested, a key tumor in which first-in-human clinical trials for AKTX-101 are planned.

AKTX-101 also demonstrated sub-nanomolar potency in several non-small cell lung cancer cell lines driven by EGFR, BRAF, and SMARCA4, as well as potent cell killing in HER2 breast cancer cell lines with inherent resistance to Topoisomerase I Inh. ADCs such as trastuzumab deruxtecan (ENHERTU™).

“These data represent a significant step forward for our lead program, AKTX-101, and reinforce our belief that a differentiated ADC payload with multiple mechanisms of action has the potential to meaningfully improve outcomes for patients with TROP2-expressing cancers,” commented Satyajit K. Mitra, Ph.D., Head of Oncology Research and Development at Akari Therapeutics. “We are seeing preclinical superior AKTX-101 potency and activity as compared to TROP2 ADCs using Topoisomerase I inhibitor payloads in bladder, lung, and breast cancer models. Together, these findings show that AKTX-101 has strong potential for targeting a broad range of cancer tumors and sub-types with superior cytotoxicity than current TROP2 ADCs that use Topoisomerase I Inhibitor payloads.”

The TROP2 ADC class continues to emerge in terms of its potential, with revenue projections expected to reach ~$12B or greater by 2033 based on current and future entrants. Akari believes that AKTX-101, with its novel RNA splicing modulator payload, can grow this class further by addressing multiple solid tumors where TROP2 is overexpressed including bladder, lung, breast, pancreatic, head and neck, and others.

Key AKTX-101 Data Presented at AACR Highlights:

• AKTX-101 demonstrated strong, single-agent anti-tumor activity across multiple models across bladder, lung, and breast cancers.
• AKTX-101 demonstrated greater potency and cell killing compared to current TROP2 ADCs, including Topoisomerase I inhibitor-resistant tumor models, as well as standard-of-care chemotherapies and targeted therapies. Combination of AKTX-101 with anti-PD-1 therapy resulted in synergistic anti-tumor efficacy and tumor regressions within in vivo models, supporting future combinations with checkpoint inhibition to maximize tumor remissions rates.
• Broad in vitro cytotoxicity was observed across a diverse panel of tumor models, including those with clinically oncogenic driver mutations including FGFR3, BRAF, EGFR, and SMARCA4.

Abizer Gaslightwala, CEO of Akari Therapeutics, added, “This data continues to add to the conviction and differentiation we have in our novel ADC payload PH1 targeting RNA splicing. We are focused on rapidly advancing AKTX-101 into the clinic, with IND-enabling studies underway and plans to submit an IND in the fourth quarter of 2026, followed by initiation of a Phase 1 study in the first quarter of 2027. Our team is executing against a clear development plan designed to efficiently translate these encouraging preclinical findings into clinical proof of concept.”

These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. Access the poster here.

¹ DataIntelo, TROP2-Targeted Therapies Market Report, 2026

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by late 2026/early 2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements 

This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients, and the timing of the submission of an IND and commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]

PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com. 

Investor Relations:

Chris Ward

(609) 772-7736
[email protected]   

Media Contact:

Laurene Isip

(609) 208-8121
[email protected]

Integra LifeSciences Holdings Corporation

TYLER, Texas, April 20, 2026 (GLOBE NEWSWIRE) — ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced that a Virginia-based, 255-bed nonprofit regional medical center affiliated with the Mayo Clinic Care Network is now using the ENvue™ Navigation Platform. The hospital is now performing feeding tube placement through a nursing-led bedside model, transitioning procedures from interventional radiology to trained clinical staff at the point of care.

“The transition to a nursing-led bedside model reflects a growing focus on efficiency and patient-centered care across hospital systems,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “With ENvue, care teams can perform feeding tube placement at the bedside, shifting procedures from interventional radiology to trained nursing staff and supporting a more streamlined process that reduces reliance on resource-intensive departments while maintaining clinical precision.”

The agreement marks ENvue’s 40th U.S. hospital customer. The Virginia-based medical center, serving more than 300,000 people, expands ENvue’s presence across regional health systems.

“We’re seeing growing demand for technologies that bring greater visibility and consistency to feeding tube placement,” said Marc Waldman, Vice President of Commercial at ENvue Medical. “Hospitals are looking for solutions that can be implemented across care teams, and we believe that real-time visualization helps support more standardized practices throughout the hospital.”

The ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure.

About ENvue Medical, Inc.

ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:

• ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
• ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
• Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:

KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
[email protected]

Media Contact:

KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
[email protected]

RESTON, Va., April 20, 2026 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC) has been awarded a new $75.2 million task order under the General Services Administration (GSA) Personnel and Readiness Infrastructure Support Management (PRISM) contract to provide critical support to the Naval Air Systems Command (NAVAIR). This contract expands on SAIC’s two decades of trusted collaboration with the Navy to advance critical equipment and systems needed by our warfighters.

SAIC will leverage predictive analytics and digital engineering tools to improve reliability, reduce downtime, and enhance the operational lifespan of AAE systems, which is vital to supporting global naval contingency operations. SAIC will provide engineering and sustainment services for NAVAIR’s SE, used to manage critical aviation systems and provide any troubleshooting support in real time. Additionally, SAIC will drive the development and integration of the Navy’s ARS efforts for the MQ-25 Stingray — an unmanned platform designed to extend the operational range of carrier air wings.

“For more than 20 years, we have worked hand in hand with the Navy to deliver mission-critical solutions that are grounded in science and engineering excellence and battlefield operational success,” said Barbara Supplee, SAIC Executive Vice President of the Army Navy Business Group. “This task order enables us to deliver best-in-class technologies that supports naval aviation at its core – AAE and SE sustainment – while driving revolutionary advancements for the MQ-25’s refueling capabilities.”

Supplee added, “Our teams don’t just deliver; we innovate, transform, and ensure the Navy retains the operational edge required to win tomorrow’s fight. This partnership, built on trust and proven performance, positions SAIC as the unparalleled choice for ensuring mission success across the Navy and the joint force.”

The task order supports key NAVAIR program offices such as PMA-201, responsible for common AAE; PMA-260, overseeing SE sustainment; and PMA-268, advancing ARS for the MQ-25. Managed platforms include the F/A-18 Hornet, P-8A Poseidon, SH-60 Seahawk, and MQ-25 Stingray, among others.

SAIC was awarded this contract for the company’s digital engineering tools, predictive analytics expertise, and proven relationship with the Navy. Over the past two decades, SAIC has delivered critical and innovative capabilities to sustain mission readiness and operational effectiveness for key Department of War customers. By prioritizing AAE and SE, while advancing the Navy’s MQ-25 refueling program, SAIC remains a trusted partner for driving superior performance and outcomes in the dynamic defense environment.

About SAIC 

SAIC® is a premier Fortune 500 mission integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end solutions in mission IT, enterprise IT, engineering services, and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.

We are approximately 23,000 strong; driven by mission, united by purpose, and inspired by opportunities. Headquartered in Reston, Virginia, SAIC has annual revenues of approximately $7.3 billion. For more information, visit saic.com. For ongoing news, please visit our newsroom.

Media Contact: 

Darryn James
[email protected]

Forward-Looking Statements 

Forward-Looking Statements Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, which may be viewed or obtained through the Investor Relations section of our website at saic.com or on the SEC’s website at sec.gov. Due to such risks, uncertainties and assumptions you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. SAIC expressly disclaims any duty to update any forward-looking statement provided in this release to reflect subsequent events, actual results or changes in SAIC’s expectations. SAIC also disclaims any duty to comment upon or correct information that may be contained in reports published by investment analysts or others. 

AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) — AINewsWire Editorial Coverage: For decades, GPS has operated as the invisible infrastructure underpinning modern warfare, enabling everything from precision-guided munitions to autonomous drone navigation. That assumption of reliability is now disappearing in real time. Across active conflict zones, satellite navigation signals are being jammed, spoofed and degraded at scale, turning one of the most trusted systems in defense into one of its most vulnerable. The consequences are immediate and measurable: Drones lose positioning, missions fail mid-operation and entire systems become ineffective in contested environments. As electronic warfare capabilities advance, GPS is increasingly becoming the first system adversaries attempt to disable, forcing a rapid reassessment of how modern platforms operate without it. In response, defense organizations worldwide are accelerating the search for alternatives that can function independently of satellite signals.

Against this backdrop, SPARC AI Inc. (OTC: SPAIF) (profile) has developed a software-based solution designed specifically for this new operational reality. The company’s Overwatch platform enables drones to navigate and identify targets in GPS-denied environments, without requiring any hardware modifications. In a market dominated by complex, hardware-dependent systems, SPARC AI’s approach offers a scalable, rapidly deployable alternative built for the conditions defining modern conflict. The company joins other leaders, including Swarmer Inc. (NASDAQ: SWMR), Unusual Machines Inc. (NYSE American: UMAC), AgEagle Aerial Systems Inc. (NYSE American: UAVS) and ZenaTech Inc. (NASDAQ: ZENA), that are operating at the intersection of drones, AI and defense technology and focused on autonomous and military-grade unmanned systems.

• The erosion of GPS reliability is not confined to isolated incidents; it is now a defining feature of modern warfare.
• Traditional approaches to GPS-denied navigation have largely relied on specialized hardware; SPARC AI addresses this challenge with a software-first model.
• The demand for GPS-independent navigation is not theoretical. Rather it is being driven by real-world conditions and reflected in market growth projections.
• The company is moving toward deployment in active conflict environments, including Ukraine, one of the most electronically contested battlefields in the world.
• One of the most significant differentiators for SPARC AI lies in its business model.

Click here to view the custom infographic of the SPARC AI editorial.

GPS Denial Is Now Battlefield Reality

The erosion of GPS reliability is not confined to isolated incidents; it is now a defining feature of modern warfare. Electronic warfare systems are increasingly deployed as a first line of attack, targeting satellite navigation signals to disrupt operations before kinetic engagement even begins. A recent report detailed widespread GPS interference across the Middle East, where jamming has disrupted aircraft navigation and maritime traffic, highlighting how pervasive and disruptive these tactics have become.

Nowhere is this more evident than in Ukraine, where drone warfare has become central to battlefield strategy. According to IEEE Spectrum, Ukraine may be losing approximately 10,000 drones per month, with GPS jamming cited as a primary cause. This level of attrition underscores a critical vulnerability: Drones that rely solely on GPS are highly susceptible to disruption and often rendered ineffective in contested environments.

The strategic implications extend far beyond a single conflict. As noted by The National, GPS is increasingly viewed as the “first casualty” of modern conflict, reflecting how central electronic warfare has become in military planning. This shift is forcing defense organizations to reconsider foundational assumptions about navigation, targeting and operational resilience.

Procurement strategies are already adapting. Militaries are prioritizing systems that can operate independently of satellite signals, particularly for drones and autonomous platforms where reliability is mission critical. The requirement is no longer optional; it is becoming a baseline capability for deployment in contested environments.

In that context, the need for GPS-independent navigation is not just urgent, it is foundational. Solutions that can maintain positioning and targeting accuracy without relying on vulnerable external signals are rapidly moving from niche capabilities to core requirements. SPARC AI’s Overwatch platform is designed to meet that requirement directly, offering a software-based pathway to resilient navigation in the environments where it is needed most.

Software-First Navigation Without Hardware Limits

Traditional approaches to GPS-denied navigation have largely relied on specialized hardware, including custom sensors, inertial systems and proprietary platforms. While effective in certain contexts, these solutions can be expensive, difficult to integrate and slow to deploy at scale. This creates a significant barrier for military organizations that need rapid, flexible solutions across diverse fleets.

SPARC AI addresses this challenge with a software-first model. Its proprietary Overwatch system delivers GPS-denied navigation and precision target acquisition entirely through software, eliminating the need for hardware replacement. This means existing drones can be upgraded rather than replaced, dramatically reducing both cost and deployment timelines.

The platform is designed to be hardware agnostic, enabling installation across virtually any drone system. This is a critical advantage in defense environments, where fleets often consist of multiple platforms sourced from different manufacturers. By avoiding hardware lock-in, SPARC AI expands its addressable market while simplifying adoption for military operators. The company has already demonstrated this approach through the launch of its offline-capable tactical application. This capability allows drones to operate in fully disconnected environments, reinforcing the platform’s relevance in contested battlefields.

In an industry dominated by hardware constraints, SPARC AI’s software model represents a structural shift. It enables faster deployment, lower costs and broader scalability, all qualities that align directly with the urgent needs of modern defense operations.

A Rapidly Expanding Global Market Opportunity

The demand for GPS-independent navigation is not theoretical. Rather it is being driven by real-world conditions and reflected in market-growth projections. The broader drone market is expanding rapidly, with estimates indicating growth from $73 billion in 2024 to $163.6 billion by 2030. This expansion is fueled by both military and commercial adoption.

Within that broader ecosystem, the drone navigation systems segment is growing even faster. According to Technavio, the drone navigation market is projected to grow at a 31.7% CAGR, adding approximately $27 billion in value by 2030. This reflects the increasing importance of reliable navigation in autonomous systems. The military drone segment is expected to nearly double, reaching $98 billion by 2033, according to Grand View Research. As defense budgets prioritize autonomous capabilities, navigation resilience becomes a core requirement rather than an optional feature.

Additionally, the GPS-denied navigation market itself is estimated to grow at roughly 12% CAGR through 2035, driven by military modernization and contested battlespace requirements. This highlights a long-term structural shift rather than a short-term trend.

SPARC AI sits at the intersection of these converging growth vectors. Its platform directly addresses the capability gap driving demand, positioning the company to benefit from both the expansion of drone adoption and the increasing need for GPS-independent operation.

Battlefield Validation Drives Real Credibility

In defense technology, real-world performance carries far more weight than laboratory testing. Solutions must prove themselves in contested environments where conditions are unpredictable and adversaries actively attempt to disrupt operations. This is where SPARC AI’s approach gains a critical advantage.

The company is moving toward deployment in active conflict environments, including Ukraine, one of the most electronically contested battlefields in the world. Last month, the company announced the appointment of an on-ground referral agent operating within Ukraine to deepen the company’s commercial engagement with Ukrainian defense stakeholders.

“The appointment reflects SPARC AI’s commitment to accelerating the deployment of its Overwatch GPS-denied navigation and target acquisition platform in the world’s most actively contested battlefield environment,” the announcement stated, noting the referral agent is based in-country and maintains established direct relationships with active Ukrainian defense personnel. This provides SPARC AI with a level of access and on-the-ground intelligence that cannot be replicated through remote engagement.

The scale of the challenge of disrupting operation reinforces the significance of this validation. With thousands of drones lost monthly due to electronic warfare, any solution that can maintain navigation and targeting capabilities under these conditions represents a meaningful advancement. Success in this environment demonstrates not just technical capability but operational reliability.

This level of validation is particularly important when engaging defense customers. Military procurement decisions are heavily influenced by proven performance in real-world scenarios, especially those involving active conflict. Demonstrating effectiveness under these conditions can significantly accelerate adoption.

Scalable Software Economics Drive Long-Term Value

One of the most significant differentiators for SPARC AI lies in its business model. Unlike traditional defense companies that rely on hardware manufacturing, the company operates as a software provider. This distinction has profound implications for scalability, margins and long-term growth.

Hardware-based defense solutions are constrained by production costs, supply chains and integration complexity. Each additional unit requires materials, manufacturing and logistics, limiting how quickly companies can scale. In contrast, software can be deployed across additional platforms with minimal incremental cost.

SPARC AI’s Overwatch platform benefits directly from this dynamic. Once developed, the software can be licensed and deployed across entire fleets without the need for physical production. This allows revenue to grow faster than costs, improving margins as adoption increases. The model also enables rapid global expansion. With an existing international software license, a growing referral network and partnerships such as an OEM trial in India, the company is building a commercial pathway that can scale quickly across multiple regions. Expansion into the U.S. defense market further amplifies this opportunity.

Perhaps most importantly, the platform creates a data-driven feedback loop. Each deployment generates operational data that can be used to improve the system’s performance. Over time, this creates a compounding advantage, one that becomes increasingly difficult for competitors to replicate.

In a world where drone adoption is accelerating and GPS reliability is declining, the combination of scalable software economics and mission-critical capability positions SPARC AI as a notable player in the next phase of defense technology evolution.

Drone Innovators Scale Across Defense Markets

Across global defense markets, a new generation of drone companies is rapidly advancing the integration of artificial intelligence, autonomy and military-grade unmanned systems. Recent developments highlight a shift toward scalable, software-driven platforms, domestic supply chain resilience and battlefield-proven capabilities, all of which are reshaping procurement priorities and investor focus.

Swarmer Inc. (NASDAQ: SWMR) has released the pricing and completion of its initial public offering. The announcement marks a significant milestone in the company’s growth trajectory. Swarmer priced its IPO at $5 per share, with its common stock beginning trading on the NASDAQ market under the ticker “SWMR.” This move positions the company to expand its AI-driven drone autonomy platform and scale operations. The company’s focus on software-based swarm coordination has already been validated in real-world environments.

Unusual Machines Inc.
(NYSE American: UMAC) is accelerating motor factory output at its Orlando campus. According to the company, recent changes are expected to more than double daily production. The Company is currently producing approximately 15,000 motors per month and has added second and third shifts. Updates to equipment, staffing, and factory layout are expected to increase daily production from approximately 700 to 1,500 parts per day as additional capacity comes online.

AgEagle Aerial Systems Inc.
(NYSE American: UAVS), operating under its EagleNXT brand, announced a strategic investment and joint venture aimed at expanding its presence in the counter-drone segment. The company disclosed a $10 million investment in Israel-based ThirdEye Systems and the formation of a U.S.-based joint venture to develop and produce counter-drone solutions.

ZenaTech Inc.

(NASDAQ: ZENA) is advancing its defense-focused strategy through both acquisitions and direct engagement with military stakeholders. The company announced that its ZenaDrone division will showcase AI-powered defense drones at major industry events, targeting relationships with military decision-makers and government agencies. In addition, ZenaTech is expanding its Drone-as-a-Service footprint through acquisitions, recently completing its 21st acquisition.

Taken together, these developments reflect a sector undergoing rapid transformation as autonomy, artificial intelligence and defense priorities converge. The latest updates illustrate how companies are scaling production, expanding capabilities and securing strategic partnerships to meet the demands of modern warfare and national security. As geopolitical tensions persist and unmanned systems become increasingly central to military operations, the companies operating at this intersection are not only responding to current needs but also shaping the future architecture of defense technology.

For more information, visit SPARC AI.

About AINewsWire

AINewsWire
 (AINW) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit www.AINewsWire.com

DISCLAIMER: AINewsWire (AINW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by AINW are solely those of AINW. Readers of this Article and content agree that they cannot and will not seek to hold liable AINW for any investment decisions by their readers or subscribers. AINW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, AINW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

AINW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and AINW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: 
https://www.AINewsWire.com/Disclaimer

AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
[email protected]
AINewsWire is powered by IBN

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego, Calif.

Allogene’s presentations at AACR highlight the potential of allogeneic CAR T to expand access, simplify delivery, and enable broader application of cell therapy across diseases when its inherent advantages are fully leveraged. The Company will participate in several AACR 2026 scientific forums, including:

Poster: Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma

Presenter: Mark K. O’Dair, PhD, Allogene
Session Title: CAR T Cell Targets and TME Reprogramming
Poster Number: 1535
Location: Poster Section 7, Board 17
Session Date and Time: Monday, April 20, 9:00am-12:00pm PT

Based on its foundational work in oncology, Allogene is extending its Dagger^® technology into autoimmune disease, applying its gene-edited, dual-targeting CAR T approach to target both BCMA and CD70 on malignant plasma cells as well as selectively eliminate alloreactive immune cells to promote durable persistence with reduced need for chemotherapy-based lymphodepletion. This strategy builds on the Company’s expertise in allogeneic cell therapy in advanced renal cell carcinoma and is designed to deliver a readily available, off-the-shelf treatment with the potential to transform how both cancer and autoimmune diseases are treated.

Major Symposium: Off-the-Shelf Cell Therapies for Cancer and Beyond
Presenter: David Chang, M.D., Ph.D., President, CEO and Co-Founder, Allogene Therapeutics
Title: Allogeneic CAR-T: Science at Scale (SY13-03)
Location: Room 28 – Upper Level – Convention Center
Session Date and Time: Tuesday, April 21, 12:30-2:00pm PT

The future of CAR T will be defined by its ability to reach more patients, more reliably and earlier in the course of disease. Allogene’s allogeneic approach is designed to unlock this potential across five key dimensions: speed, with on-demand availability; safety, manageable across care settings; simplicity, as a one-time outpatient treatment; scalability, enabling broad patient access; and survival, with the potential to deliver meaningful clinical outcomes. Together, these attributes represent a path toward making CAR T a more practical and widely accessible therapy.

Forum: Cell Therapy at a Crossroads: Exploring the Evolving Landscape between Autologous, Allogeneic, and In Vivo Engineering (Session: FO06)
Presenter: Zachary Roberts, M.D., Ph.D., EVP, Research and Development, CMO, Allogene Therapeutics
Location: Ballroom 20 AB – Upper Level – Convention Center
Session Date and Time: Tuesday, April 21, 5:00pm-6:30pm PT

Allogeneic CAR T therapy represents a major step forward in the evolution from autologous products. With extensive experience across both hematologic and solid tumors, Allogene has been a singular leader since the earliest days of allogeneic cell therapy and has defined a path through many of the scientific challenges the field has faced. As key trials advance Allogene is positioning allogeneic CAR T as a bridge to biologic-like manufacturing scale necessary to address an ever-growing patient demand for these life-saving products.

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In some cases, forward-looking statements may be identified by words such as “expect,” “believe,” “aim,” “plan,” “intend,” “seek,” “estimate,” “target,” “potential,” “may,” “could,” “will,” “would,” “should,” “designed to,” “working to” and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential clinical benefits, safety, tolerability, durability, efficacy and other attributes of Allogene’s product candidates and the potential for Allogene’s product candidates to transform how both cancer and autoimmune diseases are treated. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, but not limited to, risks and uncertainties inherent in clinical development (including that interim or early data may not be predictive of later or final results), patient enrollment and trial execution risks, uncertainties related to MRD testing and its clinical significance, the occurrence of adverse safety events, regulatory risks and uncertainties, manufacturing and CMC risks, reliance on third parties and licensors, competitive developments, intellectual property and contractual risks, and financial risks. These and other risks and uncertainties are described more fully in Allogene’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its most recent Annual Report on Form 10-K and other filings that Allogene may make from time to time with the SEC. All forward-looking statements in this press release speak only as of the date of this press release, and Allogene undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Dagger^® is a trademark of Allogene Therapeutics, Inc.

Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to Servier. Servier has granted Allogene exclusive rights to cema-cel in the U.S., all EU Member States and the United Kingdom. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T program. ALLO-329 (CD19/CD70) in autoimmune disease uses CRISPR gene-editing technology. 

Allogene Media/Investor Contact:

Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
[email protected]

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced the appointment of Thomas “TYT” Mogensen as Chief Executive Officer, to Tanbreez Mining A/S.

Thomas “TYT” Mogensen brings more than two decades of leadership experience across finance, infrastructure, natural resources, and business development in Greenland and the broader Nordic region. He has a strong track record of delivering operational improvements, driving financial turnarounds, and executing complex, large-scale projects.

Most recently, Mr. Mogensen served as Managing Director of Nalik Ventures A/S, the Greenlandic self-government’s business development company. During his tenure, he led a comprehensive turnaround of the organization, implementing a new strategic direction, optimizing operational processes, and overseeing a merger of the parent company with two subsidiaries. Under his leadership, Nalik Ventures improved its financial performance from a loss of DKK 88 million to a profit of DKK 28 million.

Prior to this, Mr. Mogensen worked as an independent consultant specializing in strategic financial management and business analysis, advising small and medium-sized enterprises as well as municipalities. He also held senior leadership roles including Business Director at BankNordic, where he significantly expanded market share in Greenland’s business segment, and CEO of NIRAS Greenland, where he oversaw financial management, strategic development, and project delivery across environmental and infrastructure-related initiatives, successfully growing the business and increasing turnover by approximately 200%.

Earlier in his career, Mr. Mogensen held key positions at Greenland Development A/S, contributing to major industrial projects, including the aluminium smelter initiative in Maniitsoq, and at Royal Arctic Line A/S, where he implemented advanced financial management systems.

Mr. Mogensen holds a Bachelor’s degree in Business Administration from Aalborg University and has completed extensive executive and professional training in financial management, project finance, and leadership.

Tony Sage, Chairman of CRML, commented:

“Mogensen’s extensive experience in Greenland’s business environment, combined with his proven ability to deliver strong financial and operational results, makes him the ideal leader to guide Tanbreez through the development stage of our world-class rare earth project—particularly given the value of his commercial and governmental experience in Greenland in driving this next phase forward.”

Mr. Mogensen, CEO of Tanbreez Mining A/S, commented:

“I am honored to join Tanbreez at such an important time in its development. The Company holds a unique asset of global significance, and I look forward to working with the team, stakeholders, and partners to unlock its full potential in a responsible and sustainable manner.”

About Critical Metals Corp.

Critical Metals Corp (Nasdaq: CRML) is a leading mining development company focused on critical metals and minerals, and producing strategic products essential to electrification and next generation technologies for Europe and its western world partners. Its flagship Project, Tanbreez, is one of the world’s largest, rare earth deposits and is located in Southern Greenland. The deposit is expected to have access to key transportation outlets as the area features year-round direct shipping access via deep water fjords that lead directly to the North Atlantic Ocean.

Another key asset is the Wolfsberg Lithium Project located in Carinthia, 270 km south of Vienna, Austria. The Wolfsberg Lithium Project is the first fully permitted mine in Europe and is strategically located with access to established road and rail infrastructure and is expected to be the next major producer of key lithium products to support the European market. Wolfsberg is well positioned with offtake and downstream partners to become a unique and valuable asset in an expanding geostrategic critical metals portfolio.

With this strategic asset portfolio, Critical Metals Corp is positioned to become a reliable and sustainable supplier of critical minerals essential for defense applications, the clean energy transition, and next-generation technologies in the western world.

For more information, please visit https://www.criticalmetalscorp.com/.

Cautionary Note Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include expectations of our business and the plans and objectives of management for future operations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this news release, forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “designed to” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors discussed under the “Risk Factors” section in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Critical Metals Corp.

Investor Relations: [email protected]

Media: [email protected]

Las Vegas, NV, April 20, 2026 (GLOBE NEWSWIRE) — Jet.AI Inc. (“Jet.AI” or the “Company”) (Nasdaq: JTAI), an emerging provider of high-performance GPU infrastructure and AI cloud services, today announced that the parties have agreed to extend the outside date of the merger agreement between flyExclusive, Inc. (NYSE American: FLYX) (“flyExclusive”) and Jet.AI to June 30, 2026, with closing expected in the second quarter of 2026.

“We’re enthusiastic about the deal and remain fully committed,” said Jet.AI Founder and Executive Chairman Mike Winston. “The SEC review process included comments related to flyExclusive’s disclosures for the 2023 period. The comments were addressed and fully resolved. With that progress, we are moving forward toward closing.”

flyExclusive’s Founder and Chief Executive Officer, Jim Segrave, added: “We are pleased with the transaction and remain firmly committed. Both teams have continued to work expeditiously toward closing, and we look forward to completing the combination in the second quarter.”

flyExclusive refiled its Form S-4 related to the transaction on April 14, 2026, available on SEC.gov here. Once the Form S-4 registration statement is declared effective by the Securities and Exchange Commission, the definitive proxy statement is expected to be mailed to shareholders of record promptly thereafter. Mailing of the definitive proxy statement is expected to commence a shareholder solicitation period of approximately thirty days, reflecting customary timing for broker distribution, shareholder review, and vote tabulation in advance of the special meeting, after which the parties expect to proceed to closing, subject to the satisfaction of customary closing conditions.

About Jet.AI

Jet.AI Inc. is a technology-driven company focused on deploying artificial intelligence tools and infrastructure to enhance decision-making, efficiency, and performance across complex systems. The Company is listed on the NASDAQ Capital Market under the ticker symbol “JTAI.”

Additional Information and Where to Find It

In connection with the transactions contemplated by the Amended and Restated Agreement and Plan of Merger and Reorganization, dated May 6, 2025, between Jet.AI, flyExclusive, FlyX Merger Sub, Inc., and Jet.AI SpinCo, Inc. (as amended, the “Merger Agreement”), flyExclusive has filed a Registration Statement on Form S-4 (File No. 333-284960) (the “Registration Statement”) to register the shares of flyExclusive common stock that will be issued in connection with the proposed transactions. The Registration Statement includes a proxy statement of the Company and a prospectus of flyExclusive (the “Proxy Statement/Prospectus”), and flyExclusive may file with the SEC other relevant documents concerning the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTIONS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, FLYEXCLUSIVE, AND THE PROPOSED TRANSACTIONS AND RELATED MATTERS.

A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other filings containing information about the Company, may be obtained, free of charge, at the SEC’s website at www.sec.gov when they are filed. You will also be able to obtain these documents, when they are filed, free of charge, from the Company by accessing the Company’s website at investors.jet.ai. Copies of the Registration Statement, the Proxy Statement/Prospectus and the filings with the SEC that will be incorporated by reference therein can also be obtained, without charge, by directing a request to the Company at 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV 89135, Attention: Board Secretary, or by phone at (702) 747-4000. The information on the Company’s website is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

Participants in the Solicitation of Proxies

Jet.AI, flyExclusive, and certain of their respective directors and officers may be deemed participants in the solicitation of proxies from Jet.AI’s stockholders in connection with the proposed transactions. Jet.AI’s stockholders and other interested persons may obtain, without charge, more detailed information regarding the names and interests in the proposed transactions of Jet.AI’s directors and officers in the parties’ filings with the SEC, including Jet.AI’s annual reports on Form 10-K and quarterly reports on Form 10-Q. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Jet.AI’s stockholders in connection with the proposed transactions and a description of their direct and indirect interests will be included in the definitive proxy statement/prospectus relating to the proposed transactions when it becomes available. Stockholders, potential investors and other interested persons should read the definitive proxy statement/prospectus carefully before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

No Offer or Solicitation

This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The proposed transactions are expected to be implemented solely pursuant to the legally binding definitive agreement, and which contains the material terms and conditions of the proposed transactions. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.

Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, with respect to the products and services offered by Jet.AI and the markets in which it operates, Jet.AI’s projected future results, and Jet.AI’s perception of market conditions. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our Company, our industry, our beliefs and our assumptions. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. As a result, caution must be exercised in relying on forward-looking statements, which speak only as of the date they were made. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements can be found in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and Jet.AI assumes no obligation and does not intend to update or revise these forward-looking statements, whether because of new information, future events, or otherwise, except as provided by law.

Jet.AI Investor Relations:

Gateway Group, Inc.
949-574-3860
[email protected]

AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) — BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), are keenly aware of this evolution and are leveraging their expertise as pioneers in this space. Through its diversified pipeline and strategic holdings, including a 45% ownership stake in GMP Bio, which was recently measured at more than $1 billion enterprise value, the company exemplifies how advancing science can directly influence financial positioning. As the biotech sector increasingly aligns valuation with progress rather than revenue alone, Oncotelic provides a case study in how innovation is becoming a recognized asset class. Oncotelic joins an elite group of other key companies focused on advanced biotech platforms that target disease at the genetic or molecular level, including Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Denali Therapeutics Inc. (NASDAQ: DNLI). 

• The biotechnology sector is evolving from a model centered on long-term R&D investment into one where scientific advancement can be reflected as measurable financial value.
• As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization.
• The rise of fair-value accounting in biotechnology is enabling companies to provide more transparent and timely representations of asset value.
• Institutional investors are increasingly recognizing clinical-stage biotech assets as investable opportunities, even in the absence of current revenue.
• Oncotelic Therapeutics operates directly within this convergence, combining oncology-focused drug development with AI-enabled platforms and strategic manufacturing exposure.
  

Click here to view the custom infographic of the Oncotelic Therapeutics editorial.

Scientific Progress Is Becoming Financial Value

The biotechnology sector is evolving from a model centered on long-term R&D investment into one where scientific advancement can be reflected as measurable financial value. Historically, investors relied heavily on discounted cash-flow projections tied to eventual commercialization, often leaving a gap between innovation and valuation. However, the adoption of fair-value frameworks under U.S. GAAP is beginning to bridge that gap by allowing companies to reassess asset value as clinical milestones are achieved.

Under Financial Accounting Standards Board guidance, particularly ASC 820, companies can measure the fair value of assets, including illiquid or early-stage investments, based on observable and unobservable inputs. This includes Level 3 assets, which are commonly used in biotech to value pipeline-stage programs and strategic investments. These frameworks allow companies to incorporate scientific progress, regulatory advancement and probability of success into financial reporting.

Advisory firms such as Deloitte and PwC note that in life sciences, valuation can reflects forward-looking indicators such as clinical progress and expected commercialization potential, as GAAP fair-value frameworks require assets to be measured based on market participant assumptions about future economic benefits. This approach aligns financial reporting more closely with operational reality, particularly in sectors where revenue may lag innovation by years.

This shift is particularly relevant for Oncotelic Therapeutics, which operates in a space where pipeline advancement is a primary driver of value. By aligning its financial reporting with the progression of its therapeutic programs and strategic investments, the company reflects the broader industry movement toward recognizing science itself as an asset.

Pipeline Proximity Drives Valuation Inflection

As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization. This phenomenon — often referred to as valuation inflection — is well documented across the biotech industry. Late-stage assets, particularly those approaching regulatory approval, tend to command a disproportionate share of enterprise value.

According to McKinsey & Company, value creation in biopharma is heavily concentrated in late-stage assets, with companies generating the majority of returns as products progress toward approval and commercialization, reflecting reduced risk and clearer revenue visibility. Additional industry analysis shows that assets approaching commercialization drive significant increases in company valuation due to higher probability of success and expected market entry.

This dynamic highlights a critical change in how investors assess biotech companies. Rather than focusing solely on current revenue or earnings, market participants increasingly evaluate the maturity and trajectory of pipeline assets. As a result, companies with strong late-stage programs can experience significant valuation increases even before generating commercial sales.

For Oncotelic Therapeutics, this trend is particularly relevant, given the company’s focus on advancing oncology therapeutics and its strategic positioning within high-value development pathways. As its programs progress and move closer to commercialization, the company’s valuation profile reflects the broader industry shift toward pipeline-driven value creation.

Fair-Value Accounting Gains Ground in Biotech

The rise of fair-value accounting in biotechnology is enabling companies to provide more transparent and timely representations of asset value. Under GAAP, Level 3 valuations are used to measure assets without observable market prices, relying on models that incorporate forward-looking assumptions such as expected cash flows and probability-weighted outcomes.

The ASC 820 framework defines fair value as the exit price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. It provides a structured hierarchy for the subsequent measurement of complex, illiquid assets using market-participant assumptions and the best available information, aligning financial reporting with a current, market-based view of an asset’s value.

Oncotelic Therapeutics exemplifies this approach through the remeasurement of its stake in GMP Bio, which reflects an approximate $1 billion-plus enterprise value. This demonstrates how clinical and strategic progress can translate directly into balance sheet strength, reinforcing the concept of science as a financial asset.

Institutional Capital Embraces Prerevenue Biotech

Institutional investors are increasingly recognizing clinical-stage biotech assets as investable opportunities, even in the absence of current revenue. This shift reflects a growing confidence in structured valuation methodologies that incorporate scientific progress, rather than relying solely on traditional financial metrics.

Many biotechnology companies are valued primarily on the strength of their pipelines rather than their existing revenue streams, reflecting the long development timelines and lack of early-stage earnings typical of the sector. Instead, valuation is closely tied to scientific progress, with factors such as clinical development stage, probability of success and regulatory milestones serving as key drivers of equity value. This approach underscores that value creation in biotech often occurs well before commercialization, as investors increasingly rely on milestone-based and probability-adjusted models to assess future potential.

Within this context, Oncotelic Therapeutics is positioned to benefit from growing institutional interest in pipeline-driven valuation. Its diversified portfolio and strategic investments align with the types of assets that are increasingly attracting capital in the biotech sector.

AI, GMP and Commercial Readiness Converge

Advancements in AI-driven drug development and GMP-compliant manufacturing are accelerating timelines and improving scalability across the biotech industry. These technologies enable more efficient clinical development, better data analysis and streamlined production processes, reducing both time and cost to market.

AI is increasingly being used to identify drug targets, optimize trial design and analyze complex datasets, improving the probability of success in clinical programs. At the same time, GMP-compliant manufacturing platforms are enabling more reliable and scalable production, which is critical as therapies move toward commercialization.

Research indicates that data-driven approaches are becoming central to biopharma value creation, with AI and advanced analytics playing a key role in accelerating development timelines. These advancements enhance the reliability of valuation models by reducing uncertainty and improving execution. This convergence of AI, manufacturing and clinical development is reshaping how value is created and measured in biotech. Companies that can integrate these capabilities are better positioned to advance therapies efficiently while maintaining regulatory compliance.

Oncotelic Therapeutics operates directly within this convergence, combining oncology-focused drug development with AI-enabled platforms and strategic manufacturing exposure. This integrated approach supports both scientific advancement and financial valuation, positioning the company within one of the most significant growth trends in the biotechnology sector.

The biotechnology sector is entering a new phase in which scientific progress is no longer viewed solely as a cost center but as a measurable financial asset. As fair-value accounting, pipeline maturity and AI-driven development reshape the industry, the traditional gap between innovation and valuation is narrowing.

Companies such as Oncotelic Therapeutics illustrate how this transformation is unfolding in real time, demonstrating that clinical advancement can materially strengthen financial positioning even before revenue generation begins. As investors increasingly focus on pipeline-driven value, the ability to translate science into measurable economic impact is becoming one of the defining characteristics of modern biotech.

From Research Spend to Revenue-Ready Assets

A new wave of biotechnology innovation is increasingly blurring the line between scientific progress and financial value creation. As drug candidates targeting disease at the genetic and molecular level advance through clinical development in 2026, progress is no longer viewed solely as research expenditure but as a measurable and evolving asset. Recent updates across the sector highlight how advancements in RNA interference, gene therapy and targeted delivery platforms are not only improving clinical outcomes but also enhancing the underlying value of biotech pipelines.

Sarepta Therapeutics Inc.
 (NASDAQ: SRPT) announced approval of its clinical trial application for SRP-1005, its investigational treatment for Huntington’s disease. Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investigational small interfering RNA (siRNA) therapeutic. INSIGHTT is a phase 1, multicenter, dose-escalation study that will evaluate the safety and tolerability of subcutaneous dosing of SRP-1005 in approximately 24 participants.

Alnylam Pharmaceuticals Inc.
 (NASDAQ: ALNY) reported new clinical and real-world data from its cardiovascular (CV) portfolio. The data was presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26). The new data continues to support the benefits of vutrisiran in transthyretin amyloid cardiomyopathy (ATTR-CM), as well as the potential of zilebesiran for hypertension, underscoring the versatility of RNAi therapeutics across cardiovascular diseases. 

Arcturus Therapeutics Holdings Inc.
(NASDAQ: ARCT) is advancing a suite of messenger RNA (mRNA)–based therapies. The company’s Q4 update highlights progress in both rare diseases and vaccine platforms, including its lead candidate, ARCT-032, an inhaled mRNA therapy for cystic fibrosis, which has demonstrated favorable safety and tolerability and is advancing into a phase 2 clinical study expected to begin in 2026. In addition, the update noted advancement with its ARCT-810 program for ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder, with ongoing regulatory interactions aimed at supporting future pivotal studies.

Denali Therapeutics Inc.
(NASDAQ: DNLI) is making significant progress in 2026 with its TransportVehicle(TM) platform. The platform is designed to enable the delivery of biologics across the blood-brain barrier, one of the most persistent challenges in treating neurological diseases. The company has outlined 2026 as a pivotal year, with plans to deliver its first TransportVehicle-enabled medicine to patients and advance two TV-enabled programs into clinical studies for Alzheimer’s disease and a program for Pompe disease.

These latest developments underscore a broader industry transition from discovery to execution, where scientific innovation is increasingly quantified in financial terms. As genetic and molecular therapies move closer to commercialization, the ability to demonstrate clinical efficacy, scalability and delivery precision is translating into tangible asset value within company pipelines. This convergence of science and finance is reshaping how biotechnology is evaluated, positioning advanced therapeutic platforms not just as research initiatives, but as structured, value-generating assets.

For more information, visit Oncotelic Therapeutics Inc.

About BioMedWire

BioMedWire
 (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

Divests Older, Less Fuel-Efficient Vessels and Agrees to Acquire High Specification Scrubber-Fitted Capesize Vessel

Increased Exposure to Premium Earning Capesize Vessels Further Enhances Earnings Power and Dividend Capacity

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, has agreed to acquire a 2019 Imabari built 182,000 dwt scrubber-fitted Capesize vessel with prompt delivery expected in June 2026. Genco also announced today that it has sold two 2005-built 55,000 dwt Supramax vessels, the Genco Picardy and the Genco Predator, which delivered to buyers on March 30, 2026 and April 15, 2026, respectively.

John C. Wobensmith, Chairman and Chief Executive Officer, commented, “We are pleased to have capitalized on the strong and liquid sale and purchase market to divest older, non-core vessels at levels above recent broker estimates, demonstrating rising asset values. With a focus on enhancing our premium earning asset base, we plan to redeploy a portion of these proceeds towards a modern, high-specification Capesize vessel. By selling two older, less fuel-efficient vessels and redeploying these proceeds into a modern, fuel-efficient Capesize vessel, we continue to execute our well-defined and stated capital allocation strategy. These transactions add to our fleet growth through immediate cash flow accretion, further increased operating leverage in a rising drybulk market, and greater asset value, earnings power and dividend capacity.”

Mr. Wobensmith added, “As with our well-timed Capesize and Newcastlemax acquisitions from 2023 to 2025, we anticipate deploying the new Capesize vessel in the spot market earning a premium to benchmark indices, enhancing shareholders’ significant upside potential. With this latest acquisition, we will have invested approximately $408 million in seven modern, fuel-efficient premium earning vessels since the fourth quarter of 2023 and a total of $557 million since 2021. Supported by an industry-leading balance sheet and significant undrawn revolver availability, we remain committed to further capitalizing on compelling growth opportunities, while continuing to successfully execute the Company’s low leverage, high dividend payout strategy.”

The purchase price of the 2019 Imabari built scrubber-fitted Capesize vessel is $65 million while the gross sales price for the two 2005-built Supramaxes is $10.6 million each or $21.2 million in aggregate. We expect to report a gain on sale of the Genco Picardy of approximately $2.1 million in Q1 2026 and a gain of a similar level in Q2 2026 relating to the sale of the Genco Predator.

About Genco Shipping & Trading Limited

Genco Shipping & Trading Limited is a U.S. based drybulk ship owning company focused on the seaborne transportation of commodities globally. We transport key cargoes such as iron ore, coal, grain, steel products, bauxite, cement, nickel ore among other commodities along worldwide shipping routes. Our wholly owned high quality, modern fleet of dry cargo vessels consists of the larger Newcastlemax and Capesize vessels (major bulk) and the medium-sized Ultramax and Supramax vessels (minor bulk), enabling us to carry a wide range of cargoes. Genco’s fleet currently consists of 43 vessels with an average age of 12.5 years and an aggregate capacity of approximately 4,934,000 dwt.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements use words such as “anticipate,” “budget,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. These forward-looking statements are based on our management’s current expectations and observations. Included among the factors that, in our view, could cause actual results to differ materially from the forward-looking statements contained in this release are the following: (i) declines or sustained weakness in demand in the drybulk shipping industry; (ii) weakness or declines in drybulk shipping rates; (iii) changes in the supply of or demand for drybulk products, generally or in particular regions; (iv) changes in the supply of drybulk carriers including newbuilding of vessels or lower than anticipated scrapping of older vessels; (v) changes in rules and regulations applicable to the cargo industry, including, without limitation, legislation adopted by international organizations or by individual countries and actions taken by regulatory authorities; (vi) changes in general domestic and international political conditions; (vii) military actions, terrorism, or piracy, including without limitation the ongoing conflicts in Ukraine and Iran, attacks on vessels in the Red Sea, and other conflicts in the Middle East and Venezuela; (viii) the completion of definitive documentation with respect to charters; (ix) charterers’ compliance with the terms of their charters in the current market environment; (x) the extent to which our operating results are affected by weakness in market conditions and freight and charter rates; (xi) outbreaks of disease such as the COVID-19 pandemic; (xii) trade conflicts, the imposition or modification of port fees, tariffs and other import restrictions, and the effectiveness and cost of any measures the Company may adopt to avoid or mitigate the impact of the foregoing, including alternate trade routes and repositioning vessels; and (xiii) other factors listed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent reports on Form 8-K and Form 10-Q). Our ability to pay dividends in any period will depend upon various factors, including the limitations under any credit agreements to which we may be a party, applicable provisions of Marshall Islands law and the final determination by the Board of Directors each quarter after its review of our financial performance, market developments, and the best interests of the Company and its shareholders. The timing and amount of dividends, if any, could also be affected by factors affecting cash flows, results of operations, required capital expenditures, or reserves. As a result, the amount of dividends actually paid may vary. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Peter Allen
Chief Financial Officer
Genco Shipping & Trading Limited
(646) 443-8550